Mydecine's new patent application may lead to a way to derive the medicinal benefits of psilocybin at lower doses.
Mydecine's new patent application may lead to a way to derive the medicinal benefits of psilocybin at lower doses.
Mind Cure's latest addition to its Scientific Advisory Board is a noted expert in psychedelic medicine, published researcher, and professor of pharmacology.
Noted psychedelic drug expert, Hamilton Morris, is the latest addition to Mind Cure's advisory board.
Field Trip will make its trading debut on Tuesday.
This is MindMed's first step in establishing a Center for Psychedelic Medicine at NYU Langone Health.
Field Trip to commence trading October 7th on the CSE, symbol "FTRP".
Field Trip announces testing of its first synthesized psychedelics molecule.
Mydecine Innovation's Mindleap subsidary launches a telehealth platform for psychedelics.
Numinus starts psilocybon cultivation operations in its 7,000 sq ft Health Canada-licensed facility.
New research initiative will compare the efficacy of psilocybin with LSD.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now